文献速递前列腺癌

COVID-19大流行对前列腺癌男性诊断和治疗的影响

Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer.
PubMed 文献 · BJU Int · 2022-02-15

本研究比较了英格兰国民健康服务体系医院在2020年首次全国封锁开始至12月31日期间与2019年同期的前列腺癌诊疗活动。结果显示新诊断前列腺癌男性减少30.8%,诊断时分期更晚且年龄略大,根治性前列腺切除术和体外放射治疗数量下降,治疗模式转向经会阴活检、大分割放疗和恩扎卢特胺。

要点

  • 2020年封锁后新诊断前列腺癌男性较2019年同期减少30.8%(22 419 vs 32 409)。
  • 2020年诊断男性分期更晚(IV期21.2% vs 17.4%)且年龄略大(≥70岁57.9% vs 55.9%;P < 0.001)。
  • 根治性前列腺切除术减少26.9%,体外放射治疗减少14.1%,治疗模式转向经会阴活检和大分割放疗。

核心结论

  • 2020年首次封锁后前列腺癌诊断和治疗数量大幅减少,新诊断男性减少约三分之一且分期更晚,治疗模式转向限制COVID-19暴露风险的方式,需要紧急协调行动以减轻对长期结局的影响。

研究设计与样本

  • 比较2020年3月23日(英格兰首次全国封锁开始)至12月31日与2019年同一日历期间英格兰国民健康服务体系医院提供前列腺癌诊疗的诊疗活动,新诊断患者来自国家快速癌症登记数据并链接其他电子医疗数据集。

主要发现

  • 2020年封锁后新诊断前列腺癌男性为22 419例,较2019年同期32 409例减少30.8%。
  • 2020年诊断男性IV期占21.2%,2019年同期为17.4%;≥70岁占57.9%,2019年同期为55.9%(P < 0.001)。
  • 2020年前列腺活检采用经会阴途径占64.0%,2019年同期为38.2%。
  • 2020年根治性前列腺切除术为3896例,较2019年同期5331例减少26.9%;体外放射治疗为9719例,较2019年同期11 309例减少14.1%。
  • 激素敏感转移性前列腺癌男性中多西他赛化疗使用减少(413 vs 1519),恩扎卢特胺使用相应增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the impact of the COVID-19 pandemic on diagnostic and treatment activity in 2020 across hospital providers of prostate cancer (PCa) care in the English National Health Service. METHODS: Diagnostic and treatment activity between 23 March (start of first national lockdown in England) and 31 December 2020 was compared with the same calendar period in 2019. Patients newly diagnosed with PCa were identified from national rapid cancer registration data linked to other electronic healthcare datasets. RESULTS: There was a 30.8% reduction (22 419 vs 32 409) in the number of men with newly diagnosed PCa in 2020 after the start of the first lockdown, compared with the corresponding period in 2019. Men diagnosed in 2020 were typically at a more advanced stage (Stage IV: 21.2% vs 17.4%) and slightly older (57.9% vs 55.9% ≥ 70 years; P < 0.001). Prostate biopsies in 2020 were more often performed using transperineal (TP) routes (64.0% vs 38.2%). The number of radical prostatectomies in 2020 was reduced by 26.9% (3896 vs 5331) and the number treated by external beam radiotherapy (EBRT) by 14.1% (9719 vs 11 309). Other changes included an increased use of EBRT with hypofractionation and reduced use of docetaxel chemotherapy in men with hormone-sensitive metastatic PCa (413 vs 1519) with related increase in the use of enzalutamide. CONCLUSION: We found substantial deficits in the number of diagnostic and treatment procedures for men with newly diagnosed PCa after the start of the first lockdown in 2020. The number of men diagnosed with PCa decreased by about one-third and those diagnosed had more advanced disease. Treatment patterns shifted towards those that limit the risk of COVID-19 exposure including increased use of TP biopsy, hypofractionated radiation, and enzalutamide. Urgent concerted action is required to address the COVID-19-related deficits in PCa services to mitigate their impact on long-term outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Nossiter J, Morris M, Parry MG, et al. Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer. BJU Int. 2022. PMID: 35080142. doi:10.1111/bju.15699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。